ERBB2 and neoplasm: In contrast, MVA-BN-HER2 immunotherapy or PD-1 blockade as monotherapies showed a significant delay in tumor growth with only a moderate increase in the median overall survival (% tumor-free mice improved from 6% (controls) to 10% or 30% after monotherapy with MVA-BN-HER2 immunotherapy or PD-1 blockade, respectively (Fig 4B and S1 Table).